A David Burden
Overview
Explore the profile of A David Burden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2968
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farag A, Visvanathan S, Bachelez H, Morita A, Lebwohl M, Barker J, et al.
J Invest Dermatol
. 2024 Jul;
145(3):573-582.e8.
PMID: 39004117
EFFISAYIL 1 was a randomized, placebo-controlled study of spesolimab, an anti-IL-36 receptor antibody, in patients presenting with a generalized pustular psoriasis flare. Treatment with spesolimab led to more rapid pustular...
2.
Hernandez-Cordero A, Thomas L, Smail A, Lim Z, Saklatvala J, Chung R, et al.
J Allergy Clin Immunol
. 2024 May;
154(3):657-665.e9.
PMID: 38815935
Background: Palmoplantar pustulosis (PPP) is an inflammatory skin disorder that mostly affects smokers and manifests with painful pustular eruptions on the palms and soles. Although the disease can present with...
3.
4.
Burden A, Bissonnette R, Anatchkova M, Budhiarso I, Skalicky A, Liberato A, et al.
J Eur Acad Dermatol Venereol
. 2024 Feb;
38(7):1383-1390.
PMID: 38334243
Background: Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disease associated with considerable patient burden. The Psoriasis Symptom Scale (PSS), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) and...
5.
Smith C, Yiu Z, Bale T, Burden A, Coates L, Eckert E, et al.
Br J Dermatol
. 2023 Sep;
190(2):270-272.
PMID: 37740557
No abstract available.
6.
Morita A, Strober B, Burden A, Choon S, Anadkat M, Marrakchi S, et al.
Lancet
. 2023 Sep;
402(10412):1541-1551.
PMID: 37738999
Background: Spesolimab is an anti-interleukin-36 receptor monoclonal antibody approved to treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and safety of spesolimab for GPP flare prevention....
7.
Burden A, Bissonnette R, Navarini A, Murakami M, Morita A, Haeufel T, et al.
Dermatol Ther (Heidelb)
. 2023 Sep;
13(10):2279-2297.
PMID: 37731086
Introduction: We evaluated the anti-interleukin-36 receptor antibody spesolimab in patients with moderate-to-severe palmoplantar pustulosis (PPP). Methods: This phase IIb trial comprised a loading dose period to week (W) 4, then...
8.
Burden A, Bachelez H, Choon S, Marrakchi S, Tsai T, Turki H, et al.
Br J Dermatol
. 2023 Apr;
189(1):138-140.
PMID: 37075220
No abstract available.
9.
Burden A
Expert Rev Clin Immunol
. 2023 Mar;
19(5):473-481.
PMID: 36960829
Introduction: Generalized pustular psoriasis (GPP) is a rare cutaneous and systemic inflammatory disease which is characterized by flares of widespread painful pustulation of the skin, often associated with fever and...
10.
Burden A, Bissonnette R, Lebwohl M, Gloede T, Anatchkova M, Budhiarso I, et al.
J Eur Acad Dermatol Venereol
. 2023 Mar;
37(7):1327-1335.
PMID: 36854864
Background: Generalized pustular psoriasis (GPP) is a rare and life-threatening skin disease often accompanied by systemic inflammation. There are currently no standardized or validated GPP-specific measures for assessing severity. Objective:...